1.	A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100077, 10-C-0077, NCT01100944
2.	Preoperative Treatment of Patients With High Risk Thymoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: VHS07.0006a, NCT00387868
3.	Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDKO-125a-006, 2009-014338-79, NCT01011439
4.	Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDKO-125a-007, NCT01301391
5.	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110096, 11-C-0096, NCT01306045
6.	Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120151, 12-C-0151, NCT01624090
7.	Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00017361, NCT00921739